Ad is loading...
IDXX
Price
$418.55
Change
-$0.06 (-0.01%)
Updated
Nov 21 closing price
80 days until earnings call
MYGN
Price
$15.12
Change
-$0.18 (-1.18%)
Updated
Nov 21 closing price
102 days until earnings call
Ad is loading...

IDXX vs MYGN

Header iconIDXX vs MYGN Comparison
Open Charts IDXX vs MYGNBanner chart's image
IDEXX Laboratories
Price$418.55
Change-$0.06 (-0.01%)
Volume$537.1K
CapitalizationN/A
Myriad Genetics
Price$15.12
Change-$0.18 (-1.18%)
Volume$891.6K
CapitalizationN/A
IDXX vs MYGN Comparison Chart
Loading...
IDXX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
IDXX vs. MYGN commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDXX is a Buy and MYGN is a Sell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (IDXX: $418.55 vs. MYGN: $15.12)
Brand notoriety: IDXX and MYGN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: IDXX: 88% vs. MYGN: 80%
Market capitalization -- IDXX: $44.84B vs. MYGN: $1.93B
IDXX [@Medical Specialties] is valued at $44.84B. MYGN’s [@Medical Specialties] market capitalization is $1.93B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDXX’s FA Score shows that 1 FA rating(s) are green whileMYGN’s FA Score has 1 green FA rating(s).

  • IDXX’s FA Score: 1 green, 4 red.
  • MYGN’s FA Score: 1 green, 4 red.
According to our system of comparison, IDXX is a better buy in the long-term than MYGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDXX’s TA Score shows that 5 TA indicator(s) are bullish while MYGN’s TA Score has 4 bullish TA indicator(s).

  • IDXX’s TA Score: 5 bullish, 3 bearish.
  • MYGN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, IDXX is a better buy in the short-term than MYGN.

Price Growth

IDXX (@Medical Specialties) experienced а -1.20% price change this week, while MYGN (@Medical Specialties) price change was -3.57% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.47%. For the same industry, the average monthly price growth was -1.10%, and the average quarterly price growth was -2.69%.

Reported Earning Dates

IDXX is expected to report earnings on Feb 10, 2025.

MYGN is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Medical Specialties (+0.47% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDXX($44.8B) has a higher market cap than MYGN($1.93B). MYGN YTD gains are higher at: -21.003 vs. IDXX (-24.592). IDXX has higher annual earnings (EBITDA): 1.22B vs. MYGN (-197.4M). IDXX has more cash in the bank: 454M vs. MYGN (141M). MYGN has less debt than IDXX: MYGN (152M) vs IDXX (1.07B). IDXX has higher revenues than MYGN: IDXX (3.66B) vs MYGN (753M).
IDXXMYGNIDXX / MYGN
Capitalization44.8B1.93B2,325%
EBITDA1.22B-197.4M-617%
Gain YTD-24.592-21.003117%
P/E Ratio52.87N/A-
Revenue3.66B753M486%
Total Cash454M141M322%
Total Debt1.07B152M702%
FUNDAMENTALS RATINGS
IDXX vs MYGN: Fundamental Ratings
IDXX
MYGN
OUTLOOK RATING
1..100
650
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
63100
SMR RATING
1..100
1793
PRICE GROWTH RATING
1..100
6391
P/E GROWTH RATING
1..100
811
SEASONALITY SCORE
1..100
39n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDXX's Valuation (85) in the Medical Specialties industry is in the same range as MYGN (95) in the Biotechnology industry. This means that IDXX’s stock grew similarly to MYGN’s over the last 12 months.

IDXX's Profit vs Risk Rating (63) in the Medical Specialties industry is somewhat better than the same rating for MYGN (100) in the Biotechnology industry. This means that IDXX’s stock grew somewhat faster than MYGN’s over the last 12 months.

IDXX's SMR Rating (17) in the Medical Specialties industry is significantly better than the same rating for MYGN (93) in the Biotechnology industry. This means that IDXX’s stock grew significantly faster than MYGN’s over the last 12 months.

IDXX's Price Growth Rating (63) in the Medical Specialties industry is in the same range as MYGN (91) in the Biotechnology industry. This means that IDXX’s stock grew similarly to MYGN’s over the last 12 months.

MYGN's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for IDXX (81) in the Medical Specialties industry. This means that MYGN’s stock grew significantly faster than IDXX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDXXMYGN
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
71%
Momentum
ODDS (%)
Bearish Trend 1 day ago
61%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
73%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 12 days ago
69%
Bullish Trend 24 days ago
76%
Declines
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
76%
View a ticker or compare two or three
Ad is loading...
IDXX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VITNX102.270.70
+0.69%
Vanguard Instl Ttl Stk Mkt Idx I
MSFAX37.890.23
+0.61%
Morgan Stanley Inst Global Franchise I
GMCFX24.310.04
+0.16%
GMO International Equity IV
TNYRX10.950.02
+0.15%
1290 Loomis Sayles Multi-Asset Income R
PCVAX13.14N/A
N/A
Virtus NFJ Small-Cap Value A

IDXX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with MYGN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then MYGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDXX
1D Price
Change %
IDXX100%
-0.01%
MYGN - IDXX
48%
Loosely correlated
-1.18%
TFX - IDXX
46%
Loosely correlated
+1.71%
TMO - IDXX
45%
Loosely correlated
+0.64%
SNN - IDXX
43%
Loosely correlated
-0.67%
WAT - IDXX
42%
Loosely correlated
+3.00%
More

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with GMED. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then GMED could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
-1.18%
GMED - MYGN
40%
Loosely correlated
+1.58%
WAT - MYGN
39%
Loosely correlated
+3.00%
FLGT - MYGN
38%
Loosely correlated
-1.91%
VCYT - MYGN
37%
Loosely correlated
-0.66%
MTD - MYGN
36%
Loosely correlated
+2.56%
More